Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIb Study to Determine the Safety and Efficacy of Candidate INfluenza Vaccine MVA-NP+M1 in Combination With Licensed InaCTivated inflUenza Vaccine in adultS Aged 65 Years and Above

Next Previous
X
Search
Trial Profile

A Phase IIb Study to Determine the Safety and Efficacy of Candidate INfluenza Vaccine MVA-NP+M1 in Combination With Licensed InaCTivated inflUenza Vaccine in adultS Aged 65 Years and Above

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 13 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VTP 100 (Primary) ; Influenza virus vaccine
  • Indications Influenza virus infections
  • Focus Therapeutic Use
  • Acronyms INVICTUS
  • Sponsors Barinthus Biotherapeutics

    • Most Recent Events

    • 17 Nov 2019 Planned number of patients changed from 2048 to 2030.
    • 20 Nov 2018 Status changed from recruiting to discontinued due to change to recommended season flu vaccine in UK
    • 19 Jan 2018 According to a Vaccitech media release, first round of participants has been recruited with over 862 people, this marks the end of the first phase of the trial, which will open again for new participants at the start of the winter flu vaccination programme in late 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top